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pRb itself is a tumor suppressor that is inactivated in
a variety of cancers (Marshall, 1991; Weinberg, 1991).Apoptosis induced by the p53 tumor suppressor can
pRb is regulated during thecell cycle by phosphorylationattenuate cancer growth in preclinical animal models.
controlled in part by G1 cyclin/cdks (Sherr, 1994; Wein-Inactivation of the pRb proteins in mouse brain epithe-
berg, 1995). Roles for pRb in cell cycle regulation andlium by the T121 oncogene induces aberrant prolifera-
terminal differentiation have been demonstrated (Lee ettion and p53-dependent apoptosis. p53 inactivation
al., 1994; Zachsenhaus et al., 1996). At the molecularcauses aggressive tumor growth due to an 85%reduc-
level, pRb appears to act by modulating the activity oftion in apoptosis. Here, we show that E2F1 signals p53-
specific transcription factors, the best studied of whichdependent apoptosis since E2F1 deficiency causes an
is E2F1. Phosphorylation of pRb results in the activation80% apoptosis reduction. E2F1 acts upstream of p53
of E2F1, which is thought to drive the G1 to S phasesince transcriptional activation of p53 target genes is
transition. Ectopic expression of E2F1 in quiescent mam-also impaired. Yet, E2F1 deficiency does not acceler-
malian cultured cells can drive S phase entry (Johnsonate tumor growth. Unlike normal cells, tumor cell pro-
et al., 1993) and can overcome G1 arrest induced byliferation is impaired without E2F1, counterbalancing
irradiation or inhibition of G1 CDK activity (DeGregori etthe effect of apoptosis reduction. These studies may
al., 1995; Lukas et al., 1996). E2F1 activates the tran-explain the apparent paradox that E2F1 can act as both
scription of several S phase genes, such as dihydrofo-an oncogene and a tumor suppressor in experimental
late reductase, DNA polymerase a, and thymidine ki-systems.
nase, as well as several cell cycle genes including cyclin
E, cyclin D, c-myc, and E2F itself (Hinds and Weinberg,
Introduction
1994; Adams and Kaelin, 1995; Slansky and Farnham,
1996). However, the regulatory roles of E2F1 are com-
When activated by DNA damage, oncogenic events, oxi- plex, in that it can also act as a transcriptional repressor
dation stress, and other aberrant cellular states, p53
when complexed with Rb (Adams and Kaelin, 1995;
can induce apoptosis, an activity that has been linked
Weintraub et al., 1995; Sellers et al., 1996).
to its tumor suppression capacity in animal models (Pan
E2F1 was the first identified of a family of related
et al., 1997). The mechanism of p53-mediated apoptosis factors, which now includes E2F1 through 5 (Sardet et
is poorly understood, and the molecular basis for p53 al., 1995; Slansky and Farnham, 1996). The E2Fs require
induction is not known. In previous work, we developed heterodimerization with DP1 or DP2 for transcriptional
a transgenic mouse model, TgT121, in which epithelial regulation and fall into two functional subgroups. E2Fs
brain tumors are initiated by inactivation of the pRb 1–3 efficiently induce S phase entry and preferentially
proteins with an N-terminal fragment of SV40 T antigen. bind pRb, while E2F4 and 5 associate with p107 or p130
Under these conditions, the normally nondividing cho- and induce S phase weakly (Lees et al., 1993; Beijersber-
roid plexus (CP) cellsare induced to proliferate, resulting gen et al., 1994; Hijmans et al., 1995; DeGregori et al.,
in the induction of p53 target gene expression (Yin et 1997). Despite the evidence that E2F1 is involved in
al., 1997) and p53-dependent apoptosis (Symonds et cell cycle regulation, however, development proceeds
al., 1994). The high apoptosis level is responsible for normally in E2F1-deficient mice (Field et al., 1996; Yama-
dramatic attenuation of tumor growth (Symonds et al., saki et al., 1996).
In addition to cell cycle activation, E2F1 overexpres-
sion has been shown to trigger apoptosis subsequent‖ To whom correspondence should be addressed (e-mail: tvdlab@
to S phase entry of quiescent cells (Qin et al., 1994;med.unc.edu).
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al., 1995). The apoptosis is largely diminished in the CP cell proliferation and apoptosis (Saenz-Robles et al.,
1994).absence of p53 function (Kowalik et al., 1995) and can
be enhanced by exogenous p53 expression (Qin et al., To directly test whether E2F1 is required for the induc-
tion of p53-dependent apoptosis, we generated TgT1211994; Wu and Levine, 1994). Furthermore, E2F1 can in-
duce endogenous p53 expression to trigger apoptosis mice deficient in E2F1 by a series of backcrosses with
E2F12/2 mice, as described in Experimental Procedures.in the presence of survival factors (Hiebert et al., 1995).
Of the five known mammalian E2Fs, the ability to induce E2F1 is expressed in both transgenic and nontransgenic
CP at approximately equal levels based on in situ RNAapoptosis is unique to E2F1 (DeGregori et al., 1997). In
vivo, transgenic expression of Drosophila melanogaster hybridization (data not shown). Apoptosis within the CP
of several TgT121 E2F11/1, TgT121E2F11/2, and TgT121dE2F in imaginal discs induces cell death along with
DNA synthesis in some otherwise quiescent cells (Asano E2F12/2 young mice (2–11 weeks) was measured in situ
by TUNEL (Figure 1A). The apoptosis indices (AI) in con-et al., 1996; Du et al., 1996).
A role for E2F1 inapoptosis could explain the observa- trol TgT121E2F11/1 and TgT121E2F11/2 littermates aver-
aged 7.3 6 1.25% and 7.02 6 0.95%, respectively (Fig-tion that mice deficient in E2F1, while developmentally
normal, are prone to tumors with advanced age (Yama- ure 1B). This level is similar to that previously determined
for TgT121 (7.3 6 1.5%) (Symonds et al., 1994). However,saki et al., 1996). Indeed, thymocyte apoptosis at certain
maturation stages is defective in E2F12/2 mice resulting in the absence of E2F1 (TgT121E2F12/2 mice) the AI was
reduced to1.79 6 0.31% (Figure 1B). This 80% decreasein an overabundance of mature T cells (Field et al., 1996).
However, a role for E2F1 in tumor suppression is difficult in apoptosis relative to TgT121E2F11/1 littermates is com-
parable, within experimental error, to the 85% apoptosisto reconcile with its apparent ability todrive thecell cycle
and to act as an oncogene in cultured cells (Johnson reduction previously observed upon p53 inactivation
(Symonds et al., 1994; Figure 1C). These results showet al., 1994; Xu et al., 1995). The role of E2F1 in p53-
dependent apoptosis in the context of tumor suppres- that E2F1 is required for p53-mediated apoptosis in this
system and are consistent with the possibility that E2F1sion has not previously been studied.
Since E2F1-induced apoptosis in cultured cells is in- functions upstream of p53 activation.
hibitable through direct interaction with pRb (Shan et
al., 1996; Hsieh et al., 1997), inactivation of pRb family E2F1 Acts Upstream of p53
function by DNA tumor virus proteins, such as T121, may Since p53-dependent apoptosis is induced in TgT121 CP
induce apoptosis that is signaled by E2F1. To test this by inactivation of the pRb family proteins, it follows
idea invivo, we have examined the role(s) of E2F1 inp53- that E2F1 could act upstream of p53. However, another
dependent apoptosis and tumor growth in the TgT121 possibility is that E2F1 acts in a parallel pathway that
transgenic mouse model described above. In the brain is also required. As an independent test of whether E2F1
tumors of these mice (deficient in pRb family function), acts in the p53 pathway, a p53 function that is not asso-
p53-dependent apoptosis retards tumor growth, provid- ciated with CP apoptosis was assayed. We have shown
ing a model for simultaneously testing roles in p53- that the p53 responsive gene, p21WAF1, is not involved in
dependent apoptosis and tumor suppression. Here, we CP apoptosis (unpublished data). Yet, p21WAF1 expres-
examine tumor cell apoptosis and tumor growth in the sion is specifically induced by T121 and is strictly depen-presence and absence of E2F1 after interbreeding TgT121 dent on p53 (Figure 2, compare panels 2B and 2C).
mice with E2F1-deficient mice (Yamasaki et al., 1996). Thus, if E2F1 lies upstream of p53 activation, an E2F1
We show that E2F1 has a clear role in the induction deficiency would cause a reduction in p53-dependent
of p53-dependent apoptosis and, surprisingly, is also p21WAF1 expression as well as in apoptosis. Indeed, in
required for the tumor cell division cycle. the absence of E2F1, the level of p21WAF1 transcripts in
CP was reduced by 89% (Figure 2D; Table 1). Further-
more, although the induction of p21WAF1 expression rep-Results
resents the best apoptosis-independent test of p53
function in this system, similar reductions in p53-E2F1 Is Required for p53-Dependent Apoptosis
induced Mdm2 and Bax expression were also causedTgT121 transgenic mice develop highly apoptotic slow- by E2F1 deficiency (Table 1). These results show thatgrowing brain tumors and die with a t50 of 26 weeks activation of multiple p53 functions (apoptosis and(Saenz-Robles et al., 1994; Symonds et al., 1994). The
transactivation) requires E2F1 and indicate that E2F1cells targeted in these mice, choroid plexus epithelium,
lies upstream of p53 (Figure 6).normally withdraw from the cell cycle within 2 weeks
after birth and remain in a resting state thereafter. How-
ever, in TgT121 mice these cells are induced to proliferate Impact of E2F1 Inactivation on Tumor Growth
Upon p53 inactivation in TgT121 mice, the 85% apoptosisaberrantly by tissue-specific expression of T121, a trun-
cated SV40 T antigen that inactivates the Rb family pro- reduction accelerates CP tumor growth (survival t50 5 4
weeks; Symonds et al., 1994; Figure 1C). Hence,a similarteins but not p53. Tumor growth is suppressed in these
mice by the induction of p53-dependent apoptosis. In- 80% apoptosis reduction in the absence of E2F1 may be
expected toaccelerate tumor growth. Yet, E2F1 appearsactivation of p53 causes dramatic acceleration of tumor
growth due to an 85% reduction in apoptosis, and mice not to be a target for inactivation in human tumors, and
tumor development in E2F1-deficient mice occurs withdie rapidly with a t50 of 4 weeks (Symonds et al., 1994).
T121-induced apoptosis depends on inactivation of pRb long latency and in only 34% of the animals (Yamasaki
et al., 1996).proteins, since mutation of this function abolishes both
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Figure 1. E2F-1 Is Required for p53-Depen-
dent Apoptosis
(A) Representative views of the in situ TUNEL
assay in CP of TgT121E2F11/1 (a) and TgT121
E2F12/2 (b) mice. Apoptotic nuclei are stained
brown and nonapoptotic nuclei are counter-
stained with methyl green (blue). Note the di-
minished apoptosis in CP of TgT121 E2F12/2
mice.
(B) Apoptosis indices (AIs) within the CP of
TgT121 mice (2–11 weeks). In each age group,
one bar represents an average count of ten
random CP fields for one mouse. Note that
there is no significant difference in the AI of
TgT121E2F11/1 and TgT121E2F11/2 CP. TgT121
E2F11/2 mice serve as a control in some sets.
The average AI for all mice in the right panel
is shown in the left panel.
(C) The average relative AIs are compared for
TgT121 mice with no deficiency and those with
a deficiency in E2F1, p53, or Bax. The TgT121
value is 100%. The AI is reduced by 80% in
the E2F12/2 background, 85% in the p532/2
background (Symonds et al., 1994), and 50%
in the bax2/2 background (Yin et al., 1997).
Bar, 25 mm.
To determine the overall impact of E2F1 deficiency E2F1 Deficiency Interferes with the Tumor
Cell Cycleon tumor growth, we compared the survival time and
morphological development of CP tumors in TgT121 Overall tumor growth rates are determined by thecombi-
nation of cellular death and proliferation rates. AlthoughE2F11/1 and TgT121E2F12/2 mice. As previously shown,
TgT121E2F11/1 mice developed slow-growing tumors, E2F1 is clearly dispensable for most normal cell cycles,
as evidenced by normal development and survival ofwith a tumor survival t50 of 26 weeks. Death was not
substantially accelerated in TgT121E2F12/2 mice (t50 5 E2F12/2 mice (Field et al., 1996; Yamasaki et al., 1996),
it is possible that E2F1 is required for the aberrant S20 weeks, Table 2). In addition, these mice died from
hydrocephalus (excessive cerebral spinal fluid [CSF]) phase of tumor cells. To determine whether E2F1 has
a role in the induction and maintenance of aberrant CPrather than tumor burden. The impact of E2F1 on tumor
growth was independently evaluated by comparing the cell proliferation, the fraction of tumor cells in S phase
was determined in the presence or absence of E2F1 bysize of CP tumor masses in TgT121 mice with altered
E2F1 genotypes at a variety of ages. A series of sections, in situ immunodetection of BrdU incorporation (Figure
4A). TgT121E2F11/1 and TgT121E2F12/2 mice of differentspanning the entire brain and containing CP, was exam-
ined histologically. The tumor masses in TgT121E2F12/2 ages (6 to 25 weeks) were examined (Figure 4B). At all
stages, a deficiency in E2F1 caused a clear reduction inmice did not grow larger than those of TgT121 mice when
followed for up to 11 weeks (prior to overt hydrocepha- the percentage of cells in S phase compared to controls
(Figures 4B and 4C). By 6 weeks of age, there was alus; compare Figures 3B and 3E and 3C and 3F). In
contrast, CP of TgT121p532/2 mice showed enlarged tu- 42% reduction and by 25 weeks of age a 73% reduction
in the tumor cell S phase fraction relative to TgT121 con-mor masses by 4 weeks of age (compare Figures 3A
and 3D). Thus, although p53-dependent apoptosis was trols. On average, the S phase fraction was reduced by
61% in the absence of E2F1 (Table 2).severely diminished in the absence of E2F1, this did not
lead to accelerated tumor growth as occurs upon p53 Since a decrease in the number of BrdU positive cells
could result from either reduced cell cycle activity or ainactivation.
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dramatic decrease in p53-dependent apoptosis and
thus why E2F1 is not a tumor suppressor in this system.
Discussion
Our results demonstrate the biological consequences
of E2F1 inactivation to tumor development. Diminished
apoptosis in TgT121E2F12/2 epithelial brain tumors in-
dicates that E2F1 signals an oncogene-induced p53-
dependent apoptosis pathway. However, E2F1 defi-
ciency does not accelerate tumor growth due to its
requirement for efficient cell cycle activity. Thus, al-
though p53-dependent apoptosis is defective in the ab-
sence of E2F1, any impact on tumor growth is counter-
balanced by the accompanying reduction in tumor cell
proliferation.
Figure 2. E2F1 Is Upstream of p53 Activation
E2F1 Role in Signaling p53-Dependent ApoptosisCP from non-Tg (A), TgT121 (B), TgT121p532/2 (C), and TgT121E2F12/2
(D) mice was examined for p21WAF1 expression by in situ RNA hybrid- Several in vitro studies have shown apoptosis induction
ization with a p21WAF1 antisense RNA probe. The CP-containing re- associated with E2F1 activity (Qin et al., 1994; Shan and
gion is framed with dotted lines. Expression of p21WAF1 is undetect- Lee, 1994; Wu and Levine, 1994; Kowalik et al., 1995;
able in nontransgenic CP (A) but dramatically induced upon
DeGregori et al.,1997), and nowthis study demonstratesexpression of T121 (B). The expression is entirely dependent on p53
that E2F1 is required for p53-dependent apoptosis in(C). This p53-dependent p21WAF1 expression is significantly reduced
developing tumors. In the tumor model system de-in the CP of TgT121E2F12/2 (D) mice. Quantification of p21WAF1 RNA
in situ hybridization is shown in Table 1. CP, choroid plexus; Br, scribed here, apoptosis is diminished by 80% uponE2F1
brain parenchyma surrounding choroid plexus. Bar, 200 mm. deficiency, similar to the 85% apoptosis reduction upon
p53 inactivation (Table 2). This attenuation of p53-
dependent apoptosis is sufficiently large that E2F1
could be involved in inducing p53 activity. In the CP, anshortened S phase, the percentage of M phase tumor
cells was also determined. If cell proliferation is inhibited excellent measurement of p53 activity that is indepen-
dent of the p53 apoptotic function (but entirely depen-in the absence of E2F1, a reduction in the M phase
percentage should mirror the observed reduction in S dent on p53 activity) is the induction of p21WAF1 transcrip-
tion. This functional test represents the best possiblephase. M phase cells were detected by immunohisto-
chemical staining of phosphorylated histone H3 (Hend- independent assessment of p53 activation in this tissue.
Quantitative determination of p53 protein levels is diffi-zel et al., 1997). TgT121E2F11/1 and TgT121E2F11/2 CP
contained a similar percentage of M phase cells. How- cult in CP, since this tissue comprises a small fraction
(0.5%) of the brain. Moreover, p53 can be activatedever, without E2F1, there was a significant reduction in
the fraction of cells in M (Figure 5A, compare panels 5Aa without significant level increases (Lutzker and Levine,
1996). We demonstrate here that E2F1 inactivationand 5Ab and 5Ac and 5Ad). Furthermore, when com-
pared as a function of time, the relative percentage of causes a nearly 90% reduction in p21WAF1 expression
(Figure 2; Table 1). Inactivation of multiple p53 functionscells in M, like those in S, decreased over time (Figure
5B). The parallel decrease in S and M phases demon- (apoptosis and apoptosis-independent transactivation)
upon E2F1 deficiency indicates that E2F1 acts upstreamstrates that E2F1 is required for efficient tumor cell prolif-
eration. An increased effect with time indicates that the of p53. It is unlikely that E2F1 directly induces p21WAF1
(Hiyama et al., 1997, 1998) in the CP. There is no induc-cell cycle is defective but not completely inactive. The
observation that tumor cell proliferation is defective in tion of p21WAF1 in T121-expressing CP in the absence of
p53, even though E2F1 is fully functional (Figure 2C).the absence of E2F1 explains why overall tumor growth
was not accelerated in TgT121E2F12/2 mice despite a Furthermore, other unrelated p53 target genes, mdm-2
Table 1. E2F1 Is Required for p53 Target Gene Induction
Relative % Transcript Levela Reduction in
p53-Induced Level (%)
Genes (Probes) TgT121 TgT121p532/2 TgT121E2F12/2 TgT121E2F12/2
p21WAF1 100 1.2 12 89
mdm2 100 34 51 83
bax 100 13 32 81
a Transcript levels were measured using radioactive in situ RNA hybridization on the mouse CP of indicated genotypes and quantified as
described in Experimental Procedures. Absolute values of silver particle density in the CP of TgT121, TgT121p532/2, and TgT121E2F12/2 mice are
122.8, 1.5, and 14.7 for p21WAF1; 56.2, 19.1, and 29.0 for mdm2; and 94.8, 12.0, and 30.8 for bax, respectively. Relative transcript levels were
determined by taking the value in TgT121 CP as 100%.
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Table 2. E2F1 Impact on Tumor Growth
Genotype
Relative % Relative % Relative % CPE Neoplastic
tg Mutation Apoptosisa S Phaseb M Phasec Growth Survival (t50, weeks)
T121 — 100 100 ND slow 26 (n 5 16)
T121 p532/2 14 6 10 109 ND rapid 4 (n 5 4)
T121 E2F11/2 89 6 13 ND 100 slow 27 (n 5 21)
T121 E2F12/2 21 6 5 39 6 14 32 6 17 slow 20d (n 5 22)
— E2F12/2 0 0 0 none .50e (n 5 5)
All numbers represent averages of several samples (see text) and have been rounded to the nearest integer. tg 5 transgene; ND 5 not
determined.
a Relative apoptosis index where the percentage of apoptotic cells in T121 CPE (7.3% on average) is considered 100%.
b Relative percentage of S phase cells where the percentage of BrdU positive cells in T121 CPE is considered 100%.
c Relative percentage of M phase cells where the percentage of M phase cells (by phosphorylated histone H3 positivity) in T121E2F11/2 CPE
is considered 100%.
dDeath in T121 E2F12/2 mice was not due to tumor growth but to hydrocephalus, a condition caused by aberrant cerebral spinal fluid regulation,
most likely secondary to CPE malfunction.
e E2F2/2 mice develop a vareity of tumor types with 19%–34% of incidence around 18 months of age (Yamasaki et al., 1996).
and bax, are also similarly diminished in the absence of induced apoptosis (Hsieh et al., 1997; Philips et al., 1997).
Furthermore, E2F2 and E2F3 expression in cultured cellsE2F1 (Table 1).
Thus, these results are consistent with a model induces S phase but not apoptosis or p53. Only E2F1
induces apoptosis and p53 accumulation in addition towhereby T121 inactivates pRb resulting in the activation
of E2F1 and thesubsequent activation of p53 responses, S phase (DeGregori et al., 1997; Kowalik et al., 1998).
Analysis of additional tumor types will be required toincluding apoptosis (Figure 6). From our studies, it is
not possible to determine how E2F1 might induce p53 determine whether E2F1 functions broadly in tumor-
associated apoptosis. However, two recent studiesactivities. E2F1 could signal p53 directly via transcrip-
tional regulation of p53 or of p53 regulatory factors. demonstrate a role for E2F1 in p53-dependent apoptosis
during development. In the developing lens, transgenicAlternatively, the signal could be indirect via the induc-
tion of S phase chromosomal activity by E2F1. The fact expression of HPV E7, which also inactivates pRb pro-
teins, induces p53-dependent apoptosis in associationthat apoptosis is diminished by 80% without E2F1, and
yet there is still significant S phase activity (60% early with proliferation (Pan and Griep, 1995). Upon E2F1 de-
ficiency, both apoptosis and proliferation are sub-in tumor growth), indicates that there may be a direct
interaction between E2F1 and the p53 pathway. In sup- stantially reduced (McCaffrey et al., submitted). p53-
dependent neuronal apoptosis in the developing centralport of this, other studies have shown that E2F1 tran-
scriptional transactivation is not required for E2F1- nervous system of Rb2/2 embryos (Macleod et al., 1996)
Figure 3. E2F1 Inactivation Does Not Accelerate Tumor Growth
Morphology of CP tumor masses in lateral ventricles at similar positions is shown for TgT121E2F12/2 mice at 5 weeks (E) and 11 weeks (F) of
age relative to their TgT121 littermates at the same age (B and C, respectively) in comparison with TgT121p532/2 (D) relative to TgT121 (A) at 4
weeks of age. Step section analysis was carried out to insure that appropriate size comparisons were made. Bar, 250 mm.
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Figure 4. The Tumor Cell S Phase Is Defec-
tive without E2F1
(A) Shown are representative views of BrdU
immunohistochemical staining within the CP
of TgT121E2F11/1 (a and c) and TgT121E2F12/2
(b and d) mice at 6 weeks (a and b) and 11
weeks (c and d) of age. Red-stained nuclei
have incorporated BrdU. The CP of non-
transgenic mice beyond 2 weeks of age show
no positive nuclei (data not shown).
(B) The percentage of S phase cells (Experi-
mental Procedures) in CP of TgT121 mice with
altered E2F1 genotypes is shown. Each bar
represents average counts of 10 fields in CP
of a single mouse. At the left, the percentage
of S phase cells is averaged for all mice of
each genotype.
(C) The percentage of TgT121E2F12/2 S phase
cells relative to that of TgT121 littermates is
shown as a function of time. Bar, 20 mm.
also requires E2F1 (Tsai et al., 1998). The same study Rather, the E2F1 role may be a function of the unsched-
uled nature of the proliferation induced by pRb inactiva-shows that the p53-independent apoptosis in the pe-
tion. This is also true of pRb-deficient CNS neuronsripheral nervous system is unaffected by the deficiency
(Tsai et al., 1998) and lens fibroblasts (McCaffrey et al.,in E2F1. Together, these studies provide substantial evi-
submitted). In these aberrantly proliferating populations,dence that E2F1 has a key role in p53-dependent apo-
E2F1 deficiency also causes a decrease in S phase cells,ptosis associated with aberrant cell cycle activity in vivo.
while development of the normal counterparts proceeds
without effect in embryos deficient only in E2F1.
E2F1 Role in the Tumor Cell Cycle
E2F1 may be dispensable for normal cell cycles due
In thepresent study, we show that along with a reduction to the availability of several additional E2Fs in mammals.
in apoptosis, E2F1 deficiency also impairs S phase activ- Both E2F2 and E2F3 can induce S phase in cultured cells
ity within epithelial brain tumors. This observation is (Slansky and Farnham, 1996; DeGregori et al., 1997), and
especially interesting because E2F1 appears to be dis- it’s possible that one or both of these factors regulates
pensable for most normal cell cycles in mammals. E2F1- normal cell proliferation or can functionally compensate
deficient mice develop normally and live long lives. Al- for the absence of E2F1. In Drosophila, unlike mammals,
though a few tissues are anomalous (testicular atrophy, dE2F is required for normal development and its muta-
exocrine gland dysplasia [Yamasaki et al., 1996] and tion causes lengthening of the embryonic S phase (Duro-
thymic enlargement [Field et al., 1996] are common), nio et al., 1998). The presence of multiple E2Fs in mam-
most cell cycle activity seems to proceed normally. mals, however, does not overcome the requirement for
However, our studies show that epithelial brain tumor E2F1 in aberrantly proliferating CP tumor cells (this pa-
cells clearly require E2F1 for efficient proliferation as per), embryonic lens (McCaffrey et al., submitted), or
evidenced by the average 60%–70% reduction in S and CNS neurons (Tsai et al., 1998). The reason for this dis-
M phase cells, respectively (Table 2). The E2F1 require- tinction in proliferating cells is not clear. Different cir-
ment appears not to be a function of the cell type, since cumstances for proliferation (e.g., pre- vs. postdifferen-
tiation) could create distinct regulatory requirements.the CP tissue develops normally in E2F1-deficient mice.
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Figure 5. Optimal Tumor Cell Division Re-
quires E2F1
(A) Mitosis is detected by immunohistochem-
ical staining of the M phase-specific phos-
phorylated histone H3. Representative fields
are shown for TgT121 (a and c) and TgT121
E2F2/2 (b and d) at 5 weeks (a and b), 23
weeks (c), and 26 weeks (d) of age.
(B) The percentage of M phase cells in
TgT121E2F12/2 CP relative to that in TgT121
E2F11/2 CP is shown as a function of time.
Bar, 25 mm.
Alternatively, additional compensatory mechanisms (e.g., late times) may reflect multiple mutations that overcome
the E2F1-null antiproliferative effect. This would not hap-other E2Fs) may not be activated under the “aberrant”
conditions produced by pRb deficiency. pen in the natural course of tumorigenesis, which begins
in an E2F1 positive background.E2F1 inactivation wouldOur studies demonstrate that E2F1 has a significant
impact on the overall tumor growth rate. In previous not be selected for during tumorigenesis (as would the
inactivation of other proapoptotic genes such as p53),studies, we showed that the CP tumor growth rate is
inversely correlated with the apoptosis level. That is, the because tumor cell proliferation would also be impaired.
Likewise, E2F1 oncogene activation (without simultane-higher the level of p53-dependent apoptosis, the slower
the tumor growth and the longer survival time (Yin et ous inactivation of the p53 apoptoticpathway) would not
occur due to the induction of extensive p53-dependental., 1997). For example, deficiency in Bax (a p53 regu-
lated cell death inducer) (Miyashita and Reed, 1995) apoptosis.
It will be important to determine whether E2F1 is re-causes a 50% reduction in apoptosis and accelerates
tumor growth 3-fold (Yin et al., 1997). Deficiency in p53 quired for tumor cell proliferation in diverse tumor types.
E2F1 inactivation has been shown to attenuate pituitarycauses an 85% apoptosis reduction and a 7-fold in-
crease in tumor growth rate (Symonds et al., 1994). In and thyroid tumorigenesis in Rb1/2 mice (Yamasaki et
al., 1998). In an E2F1-deficient background, incidencethe absence of E2F1, apoptosis is inhibited by 80%, but
tumor growth is not accelerated. We show here that this of these tumors is reduced, and lifespan is significantly
increased. Our studies now demonstrate a mechanismis because E2F1 is also required for efficient tumor cell
proliferation. Since E2F1 is central to both the tumor by which this occurs. Thus far, the requirement for E2F1
in aberrant proliferation has involved inactivation of pRbcell cycle and to the ensuing cellular apoptotic defense,
it possesses properties of both an oncogene and a tu- (or pRb, p107, and p130). An important issue is whether
E2F1 is generally required for tumor cell proliferation ormor suppressor gene. This may explain the apparent
paradox that E2F1 can act as an oncogene in cultured is specific to the inactivation of pRb proteins. Strikingly,
most human tumors carry mutations that affect thecell transformation, and yet E2F1-deficient mice are
prone to tumorigenesis (see Introduction). The tumors known pRb pathway (Sherr, 1996). The studies pre-
sented here indicate that E2F1 could be an importantthat arise in E2F1 null mice (in a fraction of animals, at
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The following procedures were performed at room temperature un-
less otherwise stated. For BrdU immunostaining, mice were first
injected intraperitoneally with BrdU labeling reagent (Amersham Cell
Proliferation Kit) and sacrificed 1 hr later as previously described
(Wu et al., 1996). Sections were incubated in 1 N HCl for 20 min and
washed 3 times with PBS, followed by blocking with 10% normal
horse serum (NHS) in PBS. Sections were then incubated with anti-
BrdU Mab 1 nuclease (Amersham Cell Proliferation Kit), for 1 hr.
For M phase staining, sections were treated with trypsin (1 mg/ml)
in PBS for 30 min at 378C, washed twice with PBS, and blocked in
5% normal goat serum in PBS. Sections were then incubated with an
antibody (1:1000; rabbit polyclonal) against phosphorylated histone
H3, which is specific for the M phase nuclei for 1 hr. After two
washes in PBS following the primary Ab incubation, sections were
incubated with biotin-conjugated secondary Ab (1:400 with 2% NHS
in PBS) for 30 min followed by a 10 min wash with 0.1% Tween-20
in PBS. Immunocomplexes were detected using the Vectastain ABC
alkaline phosphatase kit (Vector) according to the manufacturer’s
instructions.
In Situ Detection of Apoptosis
Deparaffinized sections were treated with proteinase K (20 mg/ml)
in PBS for 15 min at room temperature. Endogenous peroxidase
activity was quenched with 2% H2O2 in PBS for 5 min. Detection
of apoptosis was performed using the in situ Apoptag kit (Oncor)
according to the manufacturer’s protocol except that the sectionsFigure 6. Model for E2F1 Role in CP Tumor Dynamics
were incubated with TdT for 15 min. Quantification of apoptosis
CP tumors are induced by the inactivation of one or more pRb was by counting 10 random fields of view at a magnification of 4003
proteins by their association with transgenically introduced T121. The per section assayed. Four experimental/control animal sets were
inactivation of pRb proteins results in the activation of E2F1 and analyzed. At least three different sections per animal were assayed,
possibly other E2Fs. In this report, E2F1 is shown to be required and the counts were averaged to obtain the apoptosis index.
for optimal S phase induction and tumor cell proliferation. Some S
phase induction in the absence of E2F1 may be driven by other In Situ RNA Hybridization
E2Fs (dashed arrow). E2F1 is also shown to be required for p53- The pBluescript KS(1/2)-mp21WAF1 (Wu et al., 1996), the pBluescript
dependent apoptosis in CP and is proposed to lie upstream of p53 KS(1/2)-mbax (Yin et al., 1997), and the pKG-mdm2 (a gift from
based on the reduction of p53-dependent apoptosis and transcrip- Dr. Gigi Lozano) plasmids were used as templates for generating
tional activation without E2F1. Dashed arrows above p53 activation probes. The p21WAF1 antisense probe was generated by T7 transcrip-
indicate that these studies do not distinguish direct induction of tion of the EcoRI-linearized template and the sense probe by T3
the p53 pathway by E2F1 and indirect induction via other S phase transcription of the XbaI-linearized template, the bax probes were
activities (see text). Previous studies have shown that Bax is induced generated as previously described (Yin et al., 1997), and the mdm2
by p53 in this system and is required for much but not all of the antisense probe was generated by T7 transcription of the SalI-
apoptosis (Yin et al., 1997). linearized template and the sense probe by T7 transcription of the
SmaI-linearized template. Probes were radioactive-labeled using
[a-35S]UTP and were used at a concentration of 5 3 104 cpm/ml. The
slides were hybridized as described (Pan and Griep, 1995; Yin etfactor in the dynamics of these tumors and may be an
al., 1997) except that autoradiography was carried out at 48C for 3
appropriate target for specific drug therapy devel- days for p21WAF1 and for 1 week for bax and mdm-2. Signal densities
opment. of RNA hybridization were quantified using NIH image 1.58. The
threshold was set such that signal in the negative control (sense
probe) was just detectable. Means were determined from 10 randomExperimental Procedures
areas of CP for each sample.
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